Research Papers:

Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma

Liu Song _, Zhang Fan, Niu Jun, Liang Benjia, Li Zequn, Wang Xilong, Jia Zhongming, Han yong, Wang Xiaohong, Cheng Kai and Yang Zhenlin

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:85163-85175. https://doi.org/10.18632/oncotarget.13209

Metrics: PDF 2412 views  |   HTML 2578 views  |   ?  


Liu Song1, Zhang Fan2, Niu Jun3, Liang Benjia3, Li Zequn3, Wang Xilong1, Jia Zhongming1, Han yong1, Wang Xiaohong1, Cheng Kai1, Yang Zhenlin1

1Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China

2Department of Oncology, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China

3Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China

Correspondence to:

Yang Zhenlin, email: [email protected]

Keywords: colon carcinoma, integrinβ6, target therapy, immunoliposomes, siRNA

Received: June 06, 2016     Accepted: October 21, 2016     Published: November 08, 2016


Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13209